SCI-160 / SciSparc - LARVOL DELTA

SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million (GlobeNewswire) - "SciSparc Ltd...announced that it has signed a non-binding letter of intent ('LOI') with an undisclosed biotechnology company to pursue the out-licensing of its SCI-160 program (the 'Assets') for the treatment of pain. According to the LOI, the biotechnology company would receive exclusive, royalty-bearing global licenses to develop and sublicense the Assets. In exchange, SciSparc would be entitled to receive payment of $3 million in ordinary shares and pre-funded warrants of the biotechnology company, as well as potentially additional payments and execution fees of approximately $3 million in cash, if certain milestones will be met."

Licensing / partnership • Pain

SciSparc Announces Rebranding and Business Updates (PRNewswire) - "Pre-clinical programs: SCI-160- An innovative and proprietary CB2 receptor agonist intended for the treatment of pain... SCI-160 (formerly THX-160) for the treatment of pain."

Preclinical • Pain